Triamcinolone acetonide suprachoroidal injectable suspension - Clearside Biomedical

Drug Profile

Triamcinolone acetonide suprachoroidal injectable suspension - Clearside Biomedical

Alternative Names: CLS-1001; CLS-1003; CLS-1004; CLS-TA; suprachoroidal CLS-TA; ZUPRATA

Latest Information Update: 01 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Clearside Biomedical
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Retinal oedema; Uveitis
  • Phase II Diabetic macular oedema
  • No development reported Ocular inflammation

Most Recent Events

  • 18 Sep 2018 Clearside announces intention to submit MAA to the EMA for non-infectious Uveitis
  • 14 Jun 2018 Clearside Biomedical completes enrolment in the phase III SAPPHIRE trial for Retinal vein occlusion (Intraocular) in the USA (NCT02980874)
  • 31 May 2018 Efficacy and adverse events data from a phase II TYBEE trial in Diabetic macular oedema released by Clearside Biomedical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top